Literature DB >> 11064505

Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group.

G Rezza1, A C Lepri, A d'Arminio Monforte, P Pezzotti, F Castelli, F Dianzani, A Lazzarin, A De Luca, M Arlotti, F Leoncini, P E Manconi, G Rizzardini, L Minoli, A Poggio, G Ippolito, A N Phillips, M Moroni.   

Abstract

CONTEXT: According to recent studies, women have lower plasma HIV RNA concentrations than men. However, these studies did not take into account the duration of HIV infection.
OBJECTIVES: To analyze the relationship between viral load and gender among individuals with known date of seroconversion.
SETTING: Sixty infectious disease clinics in Italy.
DESIGN: Cross-sectional analysis of data collected at enrollment in a cohort study. PARTICIPANTS: Injecting drug users and heterosexual contacts naive to antiretroviral therapy at enrollment (245 men; 170 women). MAIN OUTCOME MEASURES: Plasma HIV RNA concentrations, measured using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) or signal amplification b-DNA assays before antiretroviral therapy.
RESULTS: Plasma HIV RNA concentrations were similar by age and exposure category (p =.80 and p =.39, respectively). Median viral load among women was roughly half that of men (p =.002). The association between viral load and gender remained significant after fitting a two-way analysis of variance (p =.03) and after adjusting for CD4 count, modality of HIV transmission, and age at enrollment in a regression model. Viral load was 0.27 log10 copies/ml (95% confidence interval, 0.05-0.40; p =.01) lower in women (i.e., 50% lower in the raw scale).
CONCLUSIONS: Plasma HIV RNA concentrations were found to be lower among women, even when considering the duration of HIV infection. Compared with men, it is possible women should be given highly aggressive antiretroviral therapy at lower HIV-RNA concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064505     DOI: 10.1097/00042560-200009010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

1.  ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling.

Authors:  Sheila M Adams; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

2.  Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda.

Authors:  Jessica L Prodger; Jun Lai; Steven J Reynolds; Jeanne C Keruly; Richard D Moore; Jingo Kasule; Taddeo Kityamuweesi; Paul Buule; David Serwadda; Martha Nason; Adam A Capoferri; Stephen F Porcella; Robert F Siliciano; Andrew D Redd; Janet D Siliciano; Thomas C Quinn
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

Review 3.  Immune modulation by estrogens: role in CNS HIV-1 infection.

Authors:  Melinda E Wilson; Filomena O Dimayuga; Janelle L Reed; Thomas E Curry; Carol F Anderson; Avindra Nath; Annadora J Bruce-Keller
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

4.  Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.

Authors:  Beatriz Grinsztejn; Laura Smeaton; Ronald Barnett; Karin Klingman; James Hakim; Timothy Flanigan; N Kumarasamy; Thomas Campbell; Judith Currier
Journal:  Antivir Ther       Date:  2011

5.  Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Elias Woldegabriel; Lemme Kebaabetswe; Raabya Rossenkhan; Busisiwe Mlotshwa; Caitlin Bonney; Mariel Finucane; Rosemary Musonda; Sikhulile Moyo; Carolyn Wester; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

6.  HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.

Authors:  Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

7.  Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.

Authors:  Indu Mani; Peter Gilbert; Jean-Louis Sankalé; Geoffrey Eisen; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Authors:  Eline L Korenromp; Brian G Williams; George P Schmid; Christopher Dye
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

9.  Impact of schistosome infection on long-term HIV/AIDS outcomes.

Authors:  Soledad Colombe; Richard Machemba; Baltazar Mtenga; Peter Lutonja; Samuel E Kalluvya; Claudia J de Dood; Pytsje T Hoekstra; Govert J van Dam; Paul L A M Corstjens; Mark Urassa; John M Changalucha; Jim Todd; Jennifer A Downs
Journal:  PLoS Negl Trop Dis       Date:  2018-07-02

10.  HIV Viral Suppression among People Living with HIV on Antiretroviral Therapy in Haut-Katanga and Kinshasa Provinces of Democratic Republic of Congo.

Authors:  Gulzar H Shah; Lievain Maluantesa; Gina D Etheredge; Kristie C Waterfield; Osaremhen Ikhile; Roger Beni; Elodie Engetele; Astrid Mulenga
Journal:  Healthcare (Basel)       Date:  2021-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.